CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ and Igor KISS. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors. 2023. Available from: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

Basic information

• Original name: CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
• Authors: OBERMANNOVÁ, Radka (203 Czech Republic, guarantor), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution).
• Edition: 2023.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30230 Other clinical medicine subjects
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14110/23:00131953
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1016/j.annonc.2023.04.432
• UT WoS: 001037960400377
• Keywords (in Czech): COVID-19; Solid cancer; multicentric trial
• Keywords in English: COVID-19; Solid cancer; multicentric trial
• Tags: Excelence Science, MOÚ, MU
• Tags: International impact

Abstract

Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.

Links

• LM2023049, research and development project: Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministry of Education, Youth and Sports of the CR